ENvue Medical, Inc. entered into a secured financing agreement with Alpha Capital Anstalt, which agreed to provide up to $1,000,000 in aggregate principal through tranches agreed by the parties. The lender funded an initial $250,000 tranche on October 8, 2026. Amounts outstanding accrue interest at 10% per annum; following and during an Event of Default, the rate increases to the lesser of 18% per annum or the highest rate permitted by applicable law. Principal and accrued interest are due December 31, 2026, although the lender may extend maturity in three-month increments through December 31, 2028. The obligations are secured by a continuing security interest in substantially all company assets, including accounts, inventory, certain deposits, intellectual property and subsidiary equity.
Separately, holders of at least 70% of the outstanding Series X Non-Voting Convertible Preferred Stock agreed to amend its terms. The amendment sets the conversion price at $0.50 per share, subject to adjustment, and revises provisions governing subsequent equity sales, including conversion-price adjustments for certain dilutive issuances. ENvue Medical filed the Certificate of Amendment with the Delaware Secretary of State on October 12, 2026.
ENvue Medical, Inc. (FEED) is implementing a reverse stock split of its common stock at a 1-for-12 ratio, effective at 12:01 a.m. Eastern Time on September 1, 2026. The split was approved by the board under authority granted by stockholders at a special meeting on August 14, 2026 and effected through a Certificate of Amendment filed in Delaware on August 28, 2026.
Following the reverse split, the number of outstanding common shares will be reduced from 11,084,616 to approximately 923,718, while the authorized common shares remain at 40,000,000. No fractional shares will be issued; instead, positions will be rounded up to the nearest whole share. The stock will continue trading on the Nasdaq Capital Market under the symbol FEED with a new CUSIP 63008J876, and options, warrants, convertible securities and restricted stock will be proportionally adjusted so that ownership percentages and voting power remain substantially unchanged.
ENvue Medical, Inc. reported weak results for the six months ended June 30, 2026, with revenue of $892 thousand, down from $1,519 thousand a year earlier, and a net loss of $8,721 thousand. Operating loss widened to $9,185 thousand as selling, marketing, and general and administrative expenses increased significantly.
Cash and cash equivalents fell to $1,084 thousand from $4,224 thousand at year-end 2025, and the company used $7,003 thousand of cash in operating activities. The filing states that recurring losses, negative cash flows, and an accumulated deficit of $124,448 thousand raise substantial doubt about the ability to continue as a going concern.
To fund operations, the company raised equity through Series H Preferred Stock issuances and large conversions into common stock, repurchased portions of Series X Preferred Stock, and benefited from a decline in the fair value of warrant liabilities from $807 thousand to $131 thousand. Subsequent to quarter-end, it added a $50 million committed equity facility with Alpha, with 40% of proceeds required to redeem remaining Series X Preferred Stock.
ENvue Medical, Inc. held a special meeting of stockholders on August 14, 2026. Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation authorizing the Board of Directors, in its discretion and prior to the one-year anniversary of the meeting, to implement a reverse stock split of the common stock at a ratio between 1-for-2 and 1-for-50, with the exact ratio to be set and publicly announced by the Board. The reverse split proposal received 3,847,974 votes for, 1,062,981 against, and 19,288 abstentions. Stockholders also approved an adjournment proposal by 4,199,681 votes for, 594,319 against, and 136,243 abstentions, although no adjournment was ultimately made.
ENVUE Medical, Inc. entered into a new committed equity facility of up to $50.0 million with an institutional investor under a Common Shares Purchase Agreement. The company may, at its discretion, direct the investor to buy common shares over a period extending to the first day of the month following 36 months after Commencement, once resale registration for these shares is effective.
Shares sold under the agreement will be priced at 90% of the lowest volume weighted average price over the three trading days preceding each purchase date. The company must apply 40% of net proceeds to redeem outstanding Series X Preferred Stock until fully redeemed, with the balance for working capital and general corporate purposes.
Separately, a Second Amendment to the Series H Purchase Agreement increases Additional Investment Rights to $59,000,000 Stated Value (59,000 Series H Preferred shares and $53,100,000 Subscription Amount), subject to shareholder approval. The investor also agreed to exercise at least $10.0 million of these rights within twelve months after shareholder approval, with a monthly minimum of $833,333.33, adjusted downward upon specified fund-raising events.
ENvue Medical, Inc. has filed a shelf registration to offer up to $50,000,000 of common stock, warrants to purchase common stock, and units, which may be sold from time to time in one or more offerings. The company’s common stock trades on Nasdaq under the symbol FEED; on August 7, 2026, the last reported sale price was $0.40 per share.
As of August 10, 2026, the public float was approximately $7,261,689, based on 8,251,920 non‑affiliate shares at $0.88 per share, and the company is limited by General Instruction I.B.6 to primary offerings not exceeding one‑third of this float in any 12‑month period. ENvue’s capital structure includes 9,296,667 common shares outstanding and several series of convertible preferred stock that can convert into additional common shares.
The company discloses a Nasdaq delisting risk due to non‑compliance with the $1.00 minimum bid price following a prior 1‑for‑10 reverse split, and it has requested a hearing to appeal Nasdaq staff’s determination. Its independent auditor’s report for 2025 includes a going concern explanatory paragraph. Net proceeds from future offerings are expected to fund manufacturing, commercialization, R&D, potential acquisitions, general working capital, and possible repurchases of equity securities.
ENvue Medical, Inc. is asking stockholders at an August 14, 2026 virtual special meeting to approve a reverse stock split of its common stock at a ratio between 1-for-2 and 1-for-50, at the board’s discretion, through an amendment to its certificate of incorporation.
The company received a Nasdaq determination that its share price has been below the $1.00 minimum bid for 30 consecutive business days and is not currently eligible for the usual compliance period because two reverse splits were completed in 2025. The board views the new reverse split as a tool to raise the per-share price and support continued listing on The Nasdaq Capital Market, while keeping the number of authorized shares and par value unchanged.
On the July 20, 2026 record date there were 9,296,667 common shares outstanding, plus several series of preferred stock that are convertible into additional common shares. A second item, the Adjournment Proposal, would allow the meeting to be postponed to solicit more votes if needed. The board recommends voting FOR both proposals.
ENvue Medical, Inc. is calling a virtual special stockholders meeting on August 14, 2026 to vote on a reverse stock split and a related adjournment proposal.
The reverse split would amend the charter to consolidate outstanding common shares at a ratio in the range of 1-for-2 to 1-for-50, at the board’s discretion within one year. The primary stated objective is to raise the share price to comply with Nasdaq’s $1.00 minimum bid price after Nasdaq notified ENvue on July 10, 2026 that the stock traded below $1.00 for 30 consecutive business days and that the company is ineligible for a standard compliance period due to two prior reverse splits in 2025.
ENvue outlines potential benefits of maintaining its Nasdaq Capital Market listing, but also details risks that another reverse split may not sustain a higher price, could reduce liquidity and create odd-lot holdings, and that failure to regain compliance could lead to delisting. The board recommends voting “FOR” both proposals.